Shattuck Labs Q2 2025 Earnings: EPS Beats Estimate, Net Loss Narrows to $12.5 Million, R&D Expenses Down 54%

Shattuck Labs Inc (STTK) reported a Q2 2025 net loss of $12.5 million, a decrease from $21.6 million in the same quarter of the previous year. The reported EPS of -$0.24 beat the analyst estimate of -$0.25. The company has a cash balance of $50.5 million and announced an oversubscribed private placement expected to raise up to $103 million. Shattuck Labs Inc is advancing its clinical pipeline, with the anticipated start of Phase 1 clinical trials for its lead program, SL-325, in Q3 2025.

Shattuck Labs Inc (STTK), a biotechnology company focused on developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors, reported its financial results for the second quarter (Q2) 2025. The company announced a net loss of $12.5 million for the period, a significant improvement from the $21.6 million loss reported in the same quarter of the previous year. The reported earnings per share (EPS) of -$0.24 was slightly better than the analyst estimate of -$0.25.

The company's cash balance stood at approximately $50.5 million as of June 30, 2025, a decrease from the $105.3 million reported at the end of June 2024. This reduction is largely attributed to research and development (R&D) and general and administrative (G&A) expenses. R&D expenses for Q2 2025 were $8.7 million, down from $19.2 million in the same quarter of the previous year, while G&A expenses were $4.4 million, compared to $5.3 million in Q2 2024.

Shattuck Labs has been actively advancing its clinical pipeline. The company has submitted an Investigational New Drug (IND) application to evaluate its lead program, SL-325, in a Phase 1 clinical trial in healthy volunteers. The IND clearance is expected in the third quarter (Q3) 2025, and the company anticipates beginning enrollment in the trial later this quarter, subject to regulatory alignment. The Phase 1 clinical trial is expected to be completed during the second quarter (Q2) 2026.

To fund its operations and clinical development activities, Shattuck Labs has announced an oversubscribed private placement expected to raise up to $103 million. The proceeds from this placement, less offering expenses, are anticipated to fund operations into 2029. The closing of the private placement is contingent upon the clearance of the company's IND for SL-325 and the satisfaction of other customary closing conditions.

In addition to its clinical pipeline, Shattuck Labs continues to develop multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and other biologically relevant targets for the treatment of patients with inflammatory bowel disease (IBD). The company plans to nominate a lead bispecific candidate from its preclinical pipeline in 2025.

References:
[1] https://www.biospace.com/press-releases/shattuck-labs-reports-second-quarter-2025-financial-results-and-recent-business-highlights